Furthermore, the (ER)-negative PRS 313(which uses the same variants but with weights adapted to provide better prediction for ER-negative disease) was associated with breast cancer risk (HR = 1.29, 95% CI [1.25–1.33]) among BRCA1 PV carriers. Here, BRCA1 is linked to breast cancer.